Virtual Medical Academy

Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.

VMA English

Overview

In this video, Prof. Gil Yosipovitch reviews key skin and itch data supporting the efficacy
of Ebglyss® (lebrikizumab), an IL-13 inhibitor, in moderate-to-severe atopic dermatitis.
He outlines the standard endpoints used in studies of IL-13 and IL-13/4 inhibitors and
explains the concept of a stable response — defined as no or minimal fluctuations with
treatment — across key measures of skin clearance and itch relief in moderate-to-severe
AD.

This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

● Review the key skin and itch efficacy data for lebrikizumab in
moderate-to-severe atopic dermatitis.
● Describe the standard endpoints used in studies of IL-13 and IL-13/4
inhibitors in moderate-to-severe atopic dermatitis.
● Define a stable response as no or minimal fluctuations with treatment.
● Explain the clinical relevance of maintaining a stable response in
moderate-to-severe atopic dermatitis.

Start Learning
  • clock Last Update 08/2026
  • adjust Hosted